Endocyte,Inc. (NASDAQ:ECYT) Files An 8-K Other Events

Endocyte,Inc. (NASDAQ:ECYT) Files An 8-K Other Events
ITEM 8.01 Other Events.

Story continues below

As previously disclosed, in connection with the proposed merger involving Endocyte,Inc. (“Endocyte”) and Novartis AG (“Novartis”), on October31, 2018, Endocyte and Novartis filed their Premerger Notification and Report Forms (the “Filing”) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with the Antitrust Division of the United States Department of Justice and the United States Federal Trade Commission. At 11:59 p.m., Eastern time, on November30, 2018, the waiting period with respect to the Filing under the HSR Act expired. The expiration of the waiting period under the HSR Act satisfies a condition to the closing of the proposed merger. The closing of the proposed merger remains subject to other customary closing conditions, including the approval of Endocyte’s stockholders and the receipt of certain other required regulatory approvals.

Additional Information and Where to Find It

In connection with the proposed merger, Endocyte has filed and intends to file relevant materials with the Securities and Exchange Commission (the “SEC”). On November16, 2018, Endocyte filed a definitive proxy statement with the SEC and began mailing definitive proxy materials to each stockholder entitled to vote at the special meeting relating to the proposed merger. This communication is not a substitute for the proxy statement or any other document that Endocyte has filed with the SEC or has sent to its stockholders in connection with the proposed merger. Stockholders are urged to carefully read the proxy statement and any other proxy materials in their entirety (including any amendments or supplements thereto) and any other relevant documents that Endocyte will file with the SEC when they become available because they will contain important information. The proxy statement and other relevant materials (when available), and any and all documents filed by Endocyte with the SEC, may also be obtained for free at the SEC’s website at www.sec.gov. In addition, stockholders may obtain free copies of the documents filed with the SEC by Endocyte in the “Investors& News” section of its website at www.endocyte.com, or copies may be obtained, without charge, by directing a request to Corporate Secretary, Endocyte,Inc., 8910 Purdue Road, Suite250,Indianapolis,Indiana 46268 or by calling (765) 463-7175.

Participants in the Solicitation

Endocyte and its directors and executive officers may be deemed, under SEC rules, to be participants in the solicitation of proxies from Endocyte’s stockholders with respect to the proposed merger. Information regarding such individuals is set forth in Endocyte’s Annual Report on Form10-K for the year ended December31, 2017, which was filed with the SEC on February27, 2018, and its definitive proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on March23, 2018. Additional information regarding the interests of such individuals in the proposed merger is included in Endocyte’s definitive proxy statement relating to the proposed merger filed with the SEC on November16, 2018. These documents may be obtained free of charge from the SEC’s website at www.sec.govand Endocyte’s website at www.endocyte.com.


About Endocyte,Inc. (NASDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

An ad to help with our costs